Clinical trials: Urinary Bladder Neoplasm
Bladder Cancer
Early Versus Late FDG-PET/CT in Bladder Cancer
The aim of this study is to examine if late FDG-PET/CT images after intravenous FDG injection has a higher sensitivity and specificity in detecting local lymph node metastases in patients with muscle invasive BC than FDG-PET/CT…
- Trial name
- NCT03065725
- Testing
- late FDG
- Where
- 2 sites in Denmark
- Volunteers
- 179 people
- Sponsor
- Jørgen Bjerggaard Jensen
Bladder Cancer, Urinary Cancer
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
The purpose of the study is to see if we will be more able to tell what the risk is for bladder cancer to reoccur or worsen when genetics and risk factors are examined along with the stage and grade of the tumor.
- Conditions
- Bladder Cancer, Urinary Cancer, Nonmuscle Invasive Bladder Cancer
- Trial name
- NCT00582387
- Testing
- specimen samples, questionnaires
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urologic Neoplasms
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
- Trial name
- NCT00034593
- Testing
- ALIMTA, gemcitabine
- Where
- 9 sites in Finland, France and 1 more
- Sponsor
- Eli Lilly and Company
Malignant Neoplasms, Hereditary Neoplastic Syndromes
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI.
- Conditions
- Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Trial name
- NCT00026884
- Where
- United States
- Volunteers
- 5,950 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerability (the effect of drug on the body) of pembrolizumab, when given as a single agent in patients with bladder tumors.
- Conditions
- Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
- Trial name
- NCT02808143
- Testing
- BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Trial name
- NCT07660055
- Testing
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00006105
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Chicago
Bladder Cancer
Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"
Pioglitazone, an agonist of the peroxisome-proliferator-activated receptor (PPAR), is a relatively new oral anti-hyperglycemic drug.
- Trial name
- PROBE-PIO (NCT01935466)
- Testing
- Pioglitazone
- Where
- India
- Volunteers
- 6,107 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Bladder Cancer, Genomic Instability
Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.
- Trial name
- SELECT (NCT06294054)
- Testing
- neoadjuvant chemotherapy with cisplatine
- Where
- 7 sites in France
- Volunteers
- 707 people
- Sponsor
- University Hospital, Rouen
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Bladder Cancer
Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence Rate
According to clinical guidelines, endoscopic surgery (mono- or bipolar TURBT, laser resection, en bloc resection) is a standard treatment option for patients with primary non-muscle invasive bladder cancer (NMIBC) (excluding…
- Trial name
- NCT04750590
- Testing
- en bloc resection, morcellation, piecemeal resection, tissue removal by loop
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics
Bladder Cancer
Detecting Bladder Cancer Using the UroMark Test.
DETECT I is a prospective multicentre observational diagnostic study to assess the performance of the UroMark assay to rule out bladder cancer in patients with haematuria.
- Trial name
- DETECT I (NCT02676180)
- Testing
- Group
- Where
- 2 sites in United Kingdom
- Volunteers
- 3,700 people
- Sponsor
- University College, London
Urinary Bladder Neoplasms
Narrow-band Imaging Diagnostic Classification System for Bladder Tumors
The goal of this observational study is to learn about the morphological characteristics of different bladder lesions under narrow-band imaging（NBI） techniques in All patients requiring cystoscopy and biopsy.
- Trial name
- NBI (NCT05611762)
- Where
- China
- Volunteers
- 1,064 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University (Qingdao)
Bladder Cancer
Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005086
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Chicago
Bladder Cancer, Radiation Cystitis
Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer
To evaluate the efficacy and safety of intravesical hyaluronic acid (HA) instillation therapy for the prevention of radiation-induced cystitis in patients undergoing radiotherapy for bladder cancer.
- Trial name
- NCT07125924
- Testing
- Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.), Normal Saline (NS)
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp